Posters will be available on the site after July 13.
|201 Impact of COVID-19 on OUD Management and MOUD Access||William Mullen MPH, PA-C, Assoc. Director for Real World Evidence, Indivior|
|202 Risk of Treatment Failure with Paliperidone Palmitate v. Oral Antipsychotics in a Sample of Adults with Schizophrenia||H. Lynn Starr MD, Director, Clinical Development, Medical Affairs, Janssen Pharmaceuticals, Inc.|
Brianne Brown PsyD, Principal Medical Science Liaison, Janssen Therapeutics, Inc.
Ibrahim Turkoz PhD, Director of Statistics and Decision Sciences, Janssen Therapeutics, Inc.
Pamela Baker PharmD, Clinical Project Scientist, Janssen Therapeutics, Inc.
|203 Characteristics and Prison Experience for Persons with and without Intellectual Disabilities in a Southeastern U.S. Department of Corrections||Ernestine Mahar , Lab Manager, Emory University|
Jennifer Sarrett PhD; MA; MEd, Senior Lecturer, Emory University
Anne Spaulding MD, MPH, CCHP-P, Associate Professor, Emory University
Time Zone: (UTC-05:00) Central Time (US & Canada) [Change Time Zone]